Roberto Iacone, Alentis CEO
Swiss-based upstart marches toward the clinic with a unique approach to fibrosis treatment
For more than 10 years, Thomas Baumert has been carefully studying a protein called Claudin-1 (CLDN1) for its role in fibrosis. Now, hot off a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
